Pharmacology  ·  Cardiovascular

Beta-Blockers in Heart Failure

Counterintuitive mechanism, three proven agents, and practical initiation rules

• Beta-blockers help heart failure not through immediate hemodynamic support but by interrupting chronic sympathetic overactivation — the same activation that is helpful acutely injures heart muscle cells over time, reduces adrenergic responsiveness, and drives dangerous arrhythmias.
• Because beta-blockers are negative inotropes, they can transiently worsen contractility when first started; over three to six months, blocking chronic sympathetic harm allows reverse remodeling and ejection fraction typically improves significantly.
• Only three beta-blockers have proven mortality benefit in heart failure with reduced ejection fraction: carvedilol (non-selective plus alpha-1 blockade, more hypotension risk), metoprolol succinate (extended-release, beta-1 selective — not interchangeable with metoprolol tartrate), and bisoprolol (most beta-1 selective, preferred with significant reactive airway disease).
• Beta-blockers are started only when the patient is clinically stable and free of active fluid overload — initiating during acute decompensation can worsen hemodynamics before the beneficial effects develop.
• In a hospitalized patient already taking a chronic beta-blocker, the default is to continue at a reduced dose rather than stop — abrupt discontinuation causes rebound sympathetic activation and increases arrhythmia risk; it is withheld only if intravenous inotropic support or cardiogenic shock requires it.